Avanafil for the treatment of erectile dysfunction

R. Segal, A. L. Burnett

Research output: Contribution to journalReview articlepeer-review

Abstract

Erectile dysfunction is a prevalent condition afflicting millions of men worldwide and can have disastrous effects on a couple's quality of life. With the understanding of the physiology of erections and the discovery of cGMP-specific 3',5'-cyclic phosphodiesterase (PDE5) inhibitors, therapy for erectile dysfunction was revolutionized, and this class of medication became the first-line treatment option for this widespread condition. Despite the ease of use, efficacy and tolerability of the available PDE5 inhibitors, many men discontinue their use, usually related to lack of efficacy or development of adverse events. As such, research into the development of other medications within this drug class is extensive. Avanafil is a novel PDE5 inhibitor with favorable pharmacokinetic and pharmacodynamic profiles with good tolerability and limited adverse events. It was recently approved and launched in Korea, and is currently under review by the U.S. Food and Drug Administration. Its efficacy and purported role in the treatment for erectile dysfunction are reviewed here.

Original languageEnglish (US)
Pages (from-to)7-15
Number of pages9
JournalDrugs of Today
Volume48
Issue number1
DOIs
StatePublished - Jan 1 2012

Keywords

  • Avanafil
  • Erectile dysfunction
  • Phosphodiesterase 5 inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Avanafil for the treatment of erectile dysfunction'. Together they form a unique fingerprint.

Cite this